

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells


Daniele Cretella+, Claudia Fumarola+, Mara Bonelli*, Roberta Alfieri, Silvia La Monica, Graziana Digiacomio, Andrea Cavazzoni, Maricla Galetti, Daniele Generali, Pier Giorgio Petronini.

*Correspondence to:

Mara Bonelli - Department of Medicine and Surgery, University of Parma, Italy

Tel +39 0521 903766

E mail mara.bonelli@unipr.it



Supplementary Fig.2 Palbociclib combined with paclitaxel induces different effects on cell proliferation depending on the treatment schedule

MDA-MB-231 cells were incubated for 48h with 0.5 μ M palbociclib (Palb) and 10 nM paclitaxel (PTX) alone or simultaneously combined (Palb+PTX), or were treated with palbociclib for 24h and then with paclitaxel for further 48h (Palb→PTX). During the last 16h of treatment, BrdU was added and cell proliferation was assessed. Data are expressed as % of BrdU vs C and are representative of two independent experiments. *** p <0.001 vs C; ### p <0.001 vs PTX; \$\$\$ p <0.001 vs Palb+PTX.